Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus: Putting evidence into practice

Journal of General Internal Medicine

Volumn 12, Issue 9, 1997, Pages 567-580

  Vijan, Sandeep ^a   Stevens, Deryth L ^b   Herman, William H ^a   Funnell, Martha M ^b   Standiford, Connie J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Complications; Diabetes mellitus; Guideline; Non insulin dependent; Patient education; Prevention

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; SULFONYLUREA DERIVATIVE;

BLOOD GLUCOSE MONITORING; COUNSELING; HEALTH CARE ACCESS; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFE EXPECTANCY; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT EDUCATION; QUALITY OF LIFE; RETINOPATHY; REVIEW; SCREENING TEST;

ALGORITHMS; BLOOD GLUCOSE; COUNSELING; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HUMANS; HYPERTENSION; MASS SCREENING; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0030848861     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1997.07111.x     Document Type: Review

References (146)

1. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health: 1995.
2. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996;125:221-32.
3. The Diabetes Control and Complications Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409-15.
4. Krolewski AS, Czyczyk A, Janeczko D, Kopczynski J. Mortality from cardiovascular diseases among diabetics. Diabetologia. 1977; 13:345-50.
5. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123-31. Published erratum appears in Diabetologia. 1987;30:364.
6. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy; clinical application of diabetic retinopathy study findings. Ophthalmology. 1981;88(7):583-600. DRS Report Number 8.
7. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. Ophthalmology. 1991;98(suppl):766-85. ETDRS Report Number 9.
8. Brechner RJ, Cowie CC, Howie LJ, Herman WH, Will JC, Harris MI. Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA. 1993;270:1714-18.
9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VI: retinal photocoagulation. Ophthalmology. 1987;94:747-53.
10. Witkin SR, Klein R. Ophthalmologic care for persons with diabetes. JAMA. 1984;251:2534-7.
11. Harris M. Medical care for patients with diabetes: epidemiologic aspects. Ann Intern Med. 1996;24(1 pt 2):117-22.
12. Kannel W, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA. 1979;241:2035-8.
13. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study. 1984-1991. Am J Epidemiol. 1994;140:857-69.
14. Ronnemaa T, Laakso M, Pyorala K, Kallio V, Puukka P. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb. 1991;11:80-90.
15. Pyorala K, Uusitupa M, Laakso M, Siitonen B, Niskanen L, Ronnemaa T. Macrovascular complications in relation to hyperinsulinemia in non-insulin-dependent diabetes mellitus. Diabetes Metab. 1987;13:345-9.
16. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-7.
17. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor. Diabetes Care. 1995;18:1299-1304.
18. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-84.
19. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-7.
20. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Diabetes Care. 1995; 18:1113-23.
21. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study, VIII: study design, progress, and performance. Diabetologia. 1991;34:877-90.
22. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
23. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study Report 14. JAMA. 1992;268(10): 1292-300.
24. Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-35.
25. Hseuh WA, Anderson PW. Hypertension, the endothelial cell and the vascular complications of diabetes mellitus. Hypertension. 1992;20:253-63.
26. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982;285:685-8.
27. Fuller JH. Epidemiology of hypertension associated with diabetes mellitus. Hypertension. 1985;7(suppl II):II-3-7.
28. Sowers JR, Ebstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension. 1995; 26(pt 1):869-79.
29. National Center for Health Statistics. Plan and operation of the Hispanic Health and Nutrition Examination Survey, 1982-1984. In: Vital Health Stat 1. Washington, DC: Department of Health and Human Services; 1985:19. DHHS publication PHS 85-1321.
30. National High Blood Pressure Education Program Working Group. Report on hypertension in diabetes. Hypertension. 1994; 23:145-58.
31. Langer RD. General population studies of the benefits and epidemiology of hypertension. The epidemiology of hypertension control in populations. Clin Exp Hypertens. 1995;7(7):1127-44.
32. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97-104.
33. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I: reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA. 1979;242: 2562-71.
34. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with Isolated systolic hypertension. JAMA. 1996; 276:1886-92.
35. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-83.
36. Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ. 1989;298:227-30.
37. Dodson PM, Pacy PJ, Bal P, Kubicki AJ, Fletcher RF, Taylor KG. A controlled trial of a high fibre, low fat and low sodium diet for mild hypertension in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1984;27:522-6.
38. Savage S, Nagel NJ, Estaclo RO, Lukken N, Schrier RW. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis. 1995;25:836-44.
39. Chuang LM, Jou TS, Wu HP, Tseng CH, Tai TY, Lin BJ. Effect of treatment of borderline hypertension on microalbuminuria in non-insulin-dependent diabetes mellitus. J Formos Med Assoc. 1991;90:531-5.
40. Lebovitz HE, Weigmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. 1994;45(suppl 45):S150-5.
41. Hypertension in Diabetes Study III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and βblockade. Diabetes Med. 1994;11:773-82.
42. Neilson FS, Rossing P, Gall M. Skøtt P, Smidt UM, Parving HH. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1994; 43:1108-13.
43. Lewis E, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-62.
44. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-81.
45. Ravid M, Lang R, Rachmani R, Lishner M. Long-term reno-protective effect of angiotensin-converting enzyme inhibition in non insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286-9.
46. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-5.
47. Ferner C, Ferrari P, Weidman P, Keller U. Beretta-Piccoli C. Reisen WF. Antihypertensive therapy with Ca antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care. 1991;14:911-4.
48. Abbott K, Smith A, Bakris GL. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996;36:274-9.
49. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995;35:73-80.
50. Fogari R, Zoppi A, Pasotti C, et al. Comparative effects of ramipril and nitrendiplne on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. J Hum Hypertens. 1995;9:131-5.
51. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ. 1991;302: 210-6.
52. Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the Systolic Hypertension in the Elderly Program. Hypertension. 1993;21:335-43.
53. Warram JH, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med. 1991;151:1350-6.
54. Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low and conventional-dose thiazide diuretics on insulin action in hypertensive patients with NIDDM. Diabetologia. 1995; 38:853-9.
55. Olsoson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double blind randomized trials. Eur Heart J. 1992;13:28-32.
56. Gunderson T, Kuekshus JT. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285-90.
57. Roberts WC. Recent studies on the effects of beta-blockers on blood lipid levels. Am Heart J. 1989;117:709-14.
58. Feher MD. Doxazosin therapy in the treatment of diabetic hypertension. Am Heart J. 1991;121:1291-301.
59. Bakris G, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992;41:912-9.
60. Schneider M, Lerch M, Papiri M. et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose-chlortalidone treatment in hypertensive type 2 diabetics. J Hypertens. 1996;14:669-77.
61. Dornhurst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycemic effect of hydrochlorothlazide in type II diabetics without alteration of insulin secretion. Lancet. 1985;1(8421):123-6.
62. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989;32:300-4.
63. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP.,Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-5.
64. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lan-cet. 1994;44:1383-9.
65. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-7.
66. Summary of the Second Report of the National Cholesterol Program (NCEP] Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II. JAMA. 1993;269:3015-23.
67. Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulin dependent diabetes mellitus: effect on serum lipids, lipopro-teins and hemastatic measures. Diabetes Res Cli Pract. 1994; 23:111-9.
68. Sweany A, Shapiro D, Täte A, Goldberg R, Stein E. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin dependent diabetes mellitus. Clin Ther. 1995;17:186-203.
69. Garg A, Grundy S. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723-6.
70. Shen D, Fuh MM, Shieh S, Ida Chen Y, Reaven GM. Effect of gemfi-brozil treatment in sulfonylurea-treated patients with non insulin-dependent diabetes. J Clin Endocrinol Metab. 1991;73:503-10.
71. Huttunen JK, Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5 year safety and mortality follow-up. J Intern Med. 1994;235:31-9.
72. Suarez L, Barrett-Conner E. Interaction between cigarette smok-ing and diabetes mellitus in the prediction of death attributed to cardiovascular disease. Am J Epidemiol. 1984;120:670-5.
73. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792-8.
74. The Diabetes Control and Complications Trials Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-83.
75. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168-88(pt 1) and 252-63(pt 2).
76. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168-88(pt 1) and 252-63(pt 2).
77. Klein R. Klein BEK, Moss SE. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988:260 (19):2864-71.
78. Klein R. Klein BEK, Moss SE. Relation of glycemie control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124(1 pt 2):90-6.
79. Singer DE, Nathan DM, Fogel HA, Schachat AP. Screening for diabetic retinopathy. Ann Intern Med. 1992;116:660-71.
80. Mogensen CE. Microalbumlnuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;10(6):356-60.
81. Bennet PH, Haffner S, Kasiske BL, et al. Diabetic renal disease recommendations. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995;25:107-12.
82. Delcourt C, Villatte-Cathelineau B, Vauzelle-Kervroedan F, Papoz L. Clinical correlates of advanced retinopathy in type II diabetic patients: implications for screening. J Clin Epidemiol. 1996;49(6): 679-85.
83. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124:627-32.
84. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17.
85. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care. 1989;12:24-31.
86. Sonsenko JM, Kato M, Soto R, Bild DE. Comparison of quantitative sensory-threshold measures for their association with foot ulceration in diabetic patients. Diabetes Care. 1990;13:1057-61.
87. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying patients at risk for lower extremity amputation in a primary health care setting: a prospective evaluation of simple screening criteria. Diabetes Care. 1992;15:1386-9.
88. Litzelman D, Slemenda C, Langefield C, et al. Reduction in lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes. Ann Intern Med. 1993;119:36-41.
89. Uccioli L, Faglia E, Monticone G, et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care. 1995;10:1376-8.
90. Sima AAF, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an ARl. N Engl J Med. 1988;319: 548-55.
91. Greene D, Arezzo J, Brown M, and the Zenarestat Study Group. Dose-related effects of the aldose reductase inhibitor Zenarestat on nerve sorbitol levels, nerve conduction velocity and nerve fiber density in human diabetic neuropathy. Diabetes. 1996;45:A9. Abstract.
92. Feldman EL, Stevens MJ, Greene DA. Treatment of diabetic neuropathy. In: Mazzaferri EL, Bar RS. eds. Advances in Endocrinology and Metabolism, Vol 5. St. Louis, Mo: Mosby Year Book Inc.; 1994;5:393-428.
93. Feldman EL, Stevens MJ, Greene DA. Treatment of diabetic neuropathy. In: Mazzaferri EL, Bar RS. eds. Advances in Endocrinology and Metabolism, Vol 5. St. Louis, Mo: Mosby Year Book Inc.; 1994;5:393-428.
94. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994;331:854-60.
95. Edmonds NE, Blundell MP, Morris ME, et al. Improved survival of the diabetic foot: the role of a specialized foot clinic. QJM. 1986;6:763-71.
96. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;4:1249-58.
97. McCance DR, Hanson RL, Charles M, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308:1323-8.
98. Gabbay KH, Hasty K, Breslow JL. et al. Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus. J Clin Endocrinol Metab. 1977;44:859-64.
99. Bunn HF. Evaluation of glycosylated hemoglobin in diabetic patients. Diabetes. 1981;30:613-7.
100. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 1997; 20(suppl 1):S14-7.
101. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc. 1995;95:1009-17.
102. American Diabetes Association. National standards for diabetes self-management education programs. Diabetes Care. 1995;18: 141-4.
103. Wing RR, Koeske R, Epstein LH, Nowalk MP. Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987;147:1749-53.
104. Reaven GM. Beneficial effect of moderate weight loss in older patients with non-insulin-dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc. 1985;33:93-5.
105. Watts NB, Spanheimer RG, DiGirolamo M, et al. Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1990;150:803-6.
106. Franz MJ, Horton ED Sr, Bantle JP, et al. Nutrition principles for the management of diabetes and related complications. Diabetes Care, 1994;17:490-518.
107. Jenkins DJA, Ocana A, Jenkins A, et al. Metabolic advantages of spreading the nutrient load: effects of increased meal frequency in non-insulin-dependent diabetes. Am J Clin Nutr. 1992;55:461-7.
108. Bertelsen J, Christiansen C, Thomsen C, et al. Effect of meal frequency on blood glucose, insulin and free fatty acids in NIDDM subjects. Diabetes Care. 1993;16:3-7.
109. Pavlou K, Krey NS, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr. 1989;49:1115-23.
110. Wing RR. Behavioral treatment of obesity: its application to type II diabetes. Diabetes Care. 1993;16:193-9.
111. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321: 1231-45.
112. Lebovitz HE. Sulfonylurea drugs. In: Lebovitz HE, ed. Therapy for Diabetes and Related Disorders. 2nd ed. Alexandria, Va: American Diabetes Association; 1995:116-23.
113. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellilus. N Engl J Med. 1995;333:541-9.
114. Bailey CJ, Turner RC, Metformin. N Engl J Med. 1996;334:574-9.
115. Stumvoll M, Nurjhan N, Periello G, Dailery G, Derich JE. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:550-5.
116. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med. 1994;1221:928-35.
117. Lebovitz HE. A new oral therapy for diabetes management: alpha-glucosidase inhibition with acarbose. Clin Diabetes. Nov/Dec 1995: 99-103.
118. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-9.
119. Kumar S, Boulton AJM, Beck-Nielson H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996;39:701-9.
120. Soneru IL, Agrawal L, Murphy J, Lawrence AM, Abraira C. Comparison of morning and bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care. 1993;16: 896-901.
121. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Insulin regimens in non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327: 1426-33.
122. Mills JL, Simpson JL, Driscoll SG, et al. Incidence of spontaneous abortion among normal women and women with insulin dependent diabetes whose pregnancies are identified within 21 days of conception. Diabetes in Early Pregnancy Study. N Engl J Med. 1988:319;1617-23.
123. 1c and the risk for major malformation and spontaneous abortion. Teratology. 1989;39:225-31.
124. Fuhrmann K, Reiher H, Semmler K, Fischer F, Fischer M, Glockner E. Prevention of congenital malformations in infants of insulin-dependent diabetic mothers. Diabetes Care. 1983;6:219-23.
125. Fuhrmann K, Reiher H, Semmler K, Glockner E. The effect of intensified conventional insulin therapy before and during pregnancy on the malformation rate in offspring of diabetic mothers. Exp Clin Endocrinol. 1984;83:173-7.
126. Goldman JA, Dickerd D, Feldberg D. Pregnancy outcome in patients with insulin-dependent diabetes mellitus with pre-conceptual diabetic control: a comparative study. Am J Obstet Gynecol. 1986;155:193-7.
127. Mills JL, Knopp RH, Simpson JL, et al. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med. 1988;318:671-6.
128. Steel JM, Jonstone FD, Hepburn DA, Smith A. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ. 1990;301:1070-4.
129. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic L, Main EK. Zigrang WD. Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA. 1991;265:731-6.
130. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol. 1996; 174(4): 1343-53.
131. Janz NK, Herman WH, Becker MP, et al. Diabetes and pregnancy: factors associated with seeking pre-conception care. Diabetes Care. 1995;18:157-65.
132. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner RE. Preconception care of diabetes, congenital malformations, and spontaneous abortions: a technical review. Diabetes Care. 1996;19: 514-41.
133. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy; experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994;96:451-6.
134. Brown SA. Effects of educational interventions and outcomes in diabetic adults: a meta-analysis revisited. Patient Educ Couns. 1990; 16:189-215.
135. Brown SA. Studies of educational interventions in diabetes care: a meta-analysis of findings. Nurs Res. 1988;37:223-30.
136. Clement S. Diabetes self-management education: a technical review. Diabetes Care. 1995;18:1204-14.
137. Funnell MM, Haas LB. National standards for diabetes self-management education programs: a technical review. Diabetes Care. 1995;18:100-16.
138. Goodall TA, Halford WK. Self-management of diabetes mellitus: a critical review. Health Psychol. 1991;10:1-8.
139. Gruesser M, Bott U, Ellermann P, Kronsbein P, Joergens V. Evaluation of a structured treatment and teaching program for non-insulin treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care. 1993;16:1268-75.
140. Padgett D, Mumford E, Hynes M, Carter R. Meta-analysis of the effects of educational and psychosocial interventions on management of diabetes mellitus. J Clin Epidemiol. 1988;41:1007-30.
141. Rubin RR, Peyrot M. Psychosocial problems and interventions in diabetes: a review of the literature. Diabetes Care. 1992;15:1640-57.
142. Nicolucci A, Cavaliere D, Scorpiglione N, et al. A comprehensive assessment of the avoidability of long-term complications of diabetes. Diabetes Care. 1996;19:927-33.
143. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care. 1990;13:513-21.
144. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc. 1995;95:1009-17.
145. Raz I, Soskolne V, Stein P. Influence of small-group education sessions on glucose homeostasis in NIDDM. Diabetes Care. 1990; 13:513-21.
146. Muhlhauser I, Berger J. Diabetes education and insulin therapy. When will they ever learn? J Intern Med. 1993;233:321-6.